These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32283214)

  • 1. Binding of excipients is a poor predictor for aggregation kinetics of biopharmaceutical proteins.
    Zalar M; Svilenov HL; Golovanov AP
    Eur J Pharm Biopharm; 2020 Jun; 151():127-136. PubMed ID: 32283214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational Characterization of Antibody-Excipient Interactions for Rational Excipient Selection Using the Site Identification by Ligand Competitive Saturation-Biologics Approach.
    Jo S; Xu A; Curtis JE; Somani S; MacKerell AD
    Mol Pharm; 2020 Nov; 17(11):4323-4333. PubMed ID: 32965126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients.
    Jorgensen L; Hostrup S; Moeller EH; Grohganz H
    Expert Opin Drug Deliv; 2009 Nov; 6(11):1219-30. PubMed ID: 19678792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of Electrostatic Mediated Antibody Liquid-Liquid Phase Separation by Charged and Noncharged Preferentially Excluded Excipients.
    Banks DD; Cordia JF
    Mol Pharm; 2021 Mar; 18(3):1285-1292. PubMed ID: 33555888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excipients in freeze-dried biopharmaceuticals: Contributions toward formulation stability and lyophilisation cycle optimisation.
    Bjelošević M; Zvonar Pobirk A; Planinšek O; Ahlin Grabnar P
    Int J Pharm; 2020 Feb; 576():119029. PubMed ID: 31953087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilateral Effects of Excipients on Protein Stability: Preferential Interaction Type of Excipient and Surface Aromatic Hydrophobicity of Protein.
    Wen L; Zheng X; Wang X; Lan H; Yin Z
    Pharm Res; 2017 Jul; 34(7):1378-1390. PubMed ID: 28401430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDX and In Silico Docking Reveal that Excipients Stabilize G-CSF via a Combination of Preferential Exclusion and Specific Hotspot Interactions.
    Wood VE; Groves K; Cryar A; Quaglia M; Matejtschuk P; Dalby PA
    Mol Pharm; 2020 Dec; 17(12):4637-4651. PubMed ID: 33112626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NMR spectroscopy as a characterization tool enabling biologics formulation development.
    Ma J; Pathirana C; Liu DQ; Miller SA
    J Pharm Biomed Anal; 2023 Jan; 223():115110. PubMed ID: 36308923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Protein-Excipient Microheterogeneity in Biopharmaceutical Solid-State Formulations by Confocal Fluorescence Microscopy.
    Koshari SH; Ross JL; Nayak PK; Zarraga IE; Rajagopal K; Wagner NJ; Lenhoff AM
    Mol Pharm; 2017 Feb; 14(2):546-553. PubMed ID: 28094996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine Learning Models of Antibody-Excipient Preferential Interactions for Use in Computational Formulation Design.
    Cloutier TK; Sudrik C; Mody N; Sathish HA; Trout BL
    Mol Pharm; 2020 Sep; 17(9):3589-3599. PubMed ID: 32794710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferential Interactions and the Effect of Protein PEGylation.
    Holm LS; Thulstrup PW; Kasimova MR; van de Weert M
    PLoS One; 2015; 10(7):e0133584. PubMed ID: 26230338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Protein-Excipient Interaction Hotspots Using Computational Approaches.
    Barata TS; Zhang C; Dalby PA; Brocchini S; Zloh M
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27258262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Stabilization and Destabilization of Protein Domains in Tissue-Type Plasminogen Activator Using Formulation Excipients.
    Robinson MJ; Matejtschuk P; Longstaff C; Dalby PA
    Mol Pharm; 2019 Feb; 16(2):744-755. PubMed ID: 30565948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-excipient compatibility screening--role of thermoanalytical and spectroscopic techniques.
    Chadha R; Bhandari S
    J Pharm Biomed Anal; 2014 Jan; 87():82-97. PubMed ID: 23845418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplified choice of suitable excipients within biologics formulation design using protein-protein interaction- and water activity-maps.
    Stolzke T; Brandenbusch C
    Eur J Pharm Biopharm; 2022 Jul; 176():153-167. PubMed ID: 35643368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranking mAb-excipient interactions in biologics formulations by NMR spectroscopy and computational approaches.
    Zhang C; Gossert ST; Williams J; Little M; Barros M; Dear B; Falk B; Kanthe AD; Garmise R; Mueller L; Ilott A; Abraham A
    MAbs; 2023; 15(1):2212416. PubMed ID: 37218059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering.
    Xu AY; Castellanos MM; Mattison K; Krueger S; Curtis JE
    Mol Pharm; 2019 Oct; 16(10):4319-4338. PubMed ID: 31487466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing the Optimal Formulation for Biopharmaceuticals: A New Approach Combining Molecular Dynamics and Experiments.
    Arsiccio A; Paladini A; Pattarino F; Pisano R
    J Pharm Sci; 2019 Jan; 108(1):431-438. PubMed ID: 30222976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Considerations for the Use of Polysorbates in Biopharmaceuticals.
    Jones MT; Mahler HC; Yadav S; Bindra D; Corvari V; Fesinmeyer RM; Gupta K; Harmon AM; Hinds KD; Koulov A; Liu W; Maloney K; Wang J; Yeh PY; Singh SK
    Pharm Res; 2018 May; 35(8):148. PubMed ID: 29797101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of Protein Pharmaceuticals: Recent Advances.
    Manning MC; Holcomb RE; Payne RW; Stillahn JM; Connolly BD; Katayama DS; Liu H; Matsuura JE; Murphy BM; Henry CS; Crommelin DJA
    Pharm Res; 2024 Jul; 41(7):1301-1367. PubMed ID: 38937372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.